Literature DB >> 18211808

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.

Jung-Hyun Park1, Sung-Hak Kim, Moon-Chang Choi, Juhee Lee, Do-Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim.   

Abstract

Vascular endothelial growth factor receptors (VEGFRs) perform pivotal roles in both tumor growth and angiogenesis. In this study, we report that histone deacetylase inhibitors (HDIs) induce a reduction in VEGFR1 and VEGFR2 protein expression via the inhibition of class II histone deacetylases (HDACs) in human cancer cell lines. After HDI treatment, VEGFR1 and VEGFR2 were shown to be downregulated in a proteasome-dependent manner. HDI treatment induced a reduction in the binding of heat shock protein (Hsp) 90 to VEGFR1 or VEGFR2, followed by an increase of the binding of Hsp70 to VEGFR1 or VEGFR2. However, we noted no remarkable changes in the binding of Hsp90/Hsp70 to VEGFR3. HDI treatment effectively inhibited the activities of HDAC6 and HDAC10. Furthermore, the knock-down of HDAC6 or HDAC10, which was accomplished via the siRNA transfection, induced depletion of VEGFR1 or VEGFR2 proteins. Overall, these results indicate that HDAC6 and HDAC10 play important roles in Hsp-mediated VEGFR regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211808     DOI: 10.1016/j.bbrc.2008.01.056

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

2.  Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin.

Authors:  David Kaluza; Jens Kroll; Sabine Gesierich; Tso-Pang Yao; Reinier A Boon; Eduard Hergenreider; Marc Tjwa; Lothar Rössig; Edward Seto; Hellmut G Augustin; Andreas M Zeiher; Stefanie Dimmeler; Carmen Urbich
Journal:  EMBO J       Date:  2011-08-16       Impact factor: 11.598

Review 3.  Toxoplasma gondii Hsp90: potential roles in essential cellular processes of the parasite.

Authors:  Sergio O Angel; Maria J Figueras; Maria L Alomar; Pablo C Echeverria; Bin Deng
Journal:  Parasitology       Date:  2014-02-21       Impact factor: 3.234

4.  HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance.

Authors:  Michaël Van Damme; Emerence Crompot; Nathalie Meuleman; Philippe Mineur; Dominique Bron; Laurence Lagneaux; Basile Stamatopoulos
Journal:  Epigenetics       Date:  2012-10-29       Impact factor: 4.528

Review 5.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

Review 6.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 7.  Targeting Histone Deacetylases in Diseases: Where Are We?

Authors:  Rosaria Benedetti; Mariarosaria Conte; Lucia Altucci
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

8.  Comparative genomic study of gastric epithelial cells co-cultured with Helicobacter pylori.

Authors:  Fen Wang; Li-Dan Luo; Jian-Hua Pan; Li-Hua Huang; Hong-Wei Lv; Qin Guo; Can-Xia Xu; Shou-Rong Shen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

9.  Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.

Authors:  Atul D Joshi; Nektarios Barabutis; Charalampos Birmpas; Christiana Dimitropoulou; Gagan Thangjam; Mary Cherian-Shaw; John Dennison; John D Catravas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-23       Impact factor: 5.464

10.  Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.

Authors:  Wenwen Chien; Dhong Hyun Lee; Yun Zheng; Peer Wuensche; Rosie Alvarez; Ding Ling Wen; Ahmed M Aribi; Su Ming Thean; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Mol Carcinog       Date:  2013-03-08       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.